Could Parkinson’s Gene Therapy Mark a Turning Point for Bayer?
Published on 09/23/2025 at 19:00 | Redaktion boerse-global.de
Bayer’s subsidiary AskBio has initiated a European Phase II clinical trial for its innovative gene therapy candidate, AB-1005, targeting Parkinson’s disease. This progression represents a critical milestone for the pharmaceutical conglomerate, potentially signaling a strategic inflection point after a period marked by patent expirations and strategic reviews.
From Safety to Efficacy: A Pivotal Clinical Step
The transition to a Phase II study fundamentally alters the nature of the clinical investigation. The initial Phase I trial focused primarily on establishing the safety and tolerability of AB-1005. Now, the primary objective shifts to demonstrating the therapy’s tangible therapeutic benefit for patients suffering from Parkinson’s disease. Success in this stage is a vital indicator of a drug candidate’s potential, making this a significant validation... Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
